Company Overview of Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., a technology transfer company, protects and commercializes the Hebrew University of Jerusalem’s intellectual properties worldwide. It focuses on marketing and licensing the inventions, products, and technologies developed by the university's faculty, staff, researchers, and students in various fields, including agriculture, food and nutrition, nanotechnology, chemistry and materials, humanities, research collaboration, cleantech and environment, life science and biotechnology, veterinary, computer science and engineering, micro and opto electronics, medicine and pharmaceuticals, water and environmental technologi...
Edmond J. Safra Campus
P.O. Box 39135
Founded in 1964
Key Executives for Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
President & Chief Executive Officer
Head of Research Collaborations and Vice President
Senior Vice President of Business Development
Compensation as of Fiscal Year 2017.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Key Developments
Therapix Signs Exclusive License Agreement with Yissum Research Development Company for Nasal Drug Delivery Technology
Apr 5 17
Therapix Biosciences Ltd. announced that it has signed a sublicense agreement for Yissum Research Development Company of the Hebrew University Ltd.'s nasal drug delivery technology. Under the terms of the agreement, Yissum will grant Therapix an exclusive, worldwide, sub-licensable, royalty-bearing license to its technology for the nasal delivery of cannabinoids. The technology, developed by Professor Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates administration and effective nasal absorption of tetrahydrocannabinol, or THC, the active pharmaceutical ingredient in the drugs developed by Therapix. The license agreement with Yissum has the potential to advance Therapix's strategy to develop proprietary cannabinoid delivery technologies to improve drug administration, including nasal and sublingual delivery methods for THC, with formulations designed to increase efficacy.
Kamada Announces Collaboration Agreement with Yissum for Development of a Recombinant Human Alpha 1 Antitrypsin
Nov 15 16
Kamada Ltd. announced that it has signed a collaboration agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., for the development of an efficient and robust eukaryotic expression system for recombinant human Alpha 1 Antitrypsin (rhAAT). The goal of this development work is to maximize protein yields and functionality.
Therapix Biosciences Signs a Binding Memorandum of Understandings with Yissum
Jul 5 16
Therapix Biosciences has announced that it has entered into a binding memorandum of understandings (MOU) with Yissum to receive an exclusive, worldwide license to use a patent-protected formulation for nasal administration of cannabinoid substances. The technology, developed by Prof. Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates administration and effective absorption of the active ingredient THC nasally. The MOU joins the agreement signed last week with a Swiss drug development company to receive a worldwide and exclusive license to use a formulation for sublingual administration of ultralow dosages of THC. Such two agreements form part of the progress in the company's operations in the development and marketing of the formulations for the indications on which the Company has chosen to focus, with an emphasis on treatment of cognitive impairments.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|